Track Easywell Biomedicals's current cash ($360M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest current cash for 1799.TWO is $360M as of June 2026. That compares with $230M in the prior-year period — up 54.3% year over year. Investors often review this figure alongside Easywell Biomedicals's historical trend and sector peers before judging valuation or financial health.
Over the past year, 1799.TWO's current cash moved from $230M to $360M — a 54.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Easywell Biomedicals's operating scale or balance-sheet position.
A current cash figure of $360M for 1799.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting 1799.TWO's current cash ($360M), review year-over-year change from $230M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.